ReConception Solutions aims to empower an existing and expanding group of OBGYNs to deliver front line fertility care in and office setting
OUR MISSION & VISION
Creating a world where every couple has access to affordable and effective fertility treatments
mission
vision
INFERTILITY MARKET
The fertility space is plagued by inaccessibility, high costs, inconsistent outcomes, and trauma, amplifying the need for novel treatments to aid in conception, thus encouraging more people to pursue front-line fertility options.
13.4 M
6-11%
$60k
7%
$5.71 Billion
people struggling with infertility in the u.s.
success rate of iui treatment per cycle
Average cost per live birth with ivf
of patients can access ivf
U.S. market size
ReConception Solutions has a wide range of issued patents across three unique fertility devices with global IP protection.
INTELLECTUAL PROPERTY
OUR PLATFORM
A device platform that closes the gap in fertility success through newly conceived front-line solutions, improving outcomes and reducing procedural trauma and discomfort
Intrauterine Insemination (IUI) Delivery System
Precise visual evaluation & abrasion system
At-home semen collection & filtration system
Disclaimer: The medical devices discussed on this website have not been approved or cleared by the U.S. Food and Drug Administration (FDA). These products are not intended for use in diagnosing, treating, curing, or preventing any disease. Please consult a licensed healthcare professional before using any medical device.
Click here for a demo of our iui delivery system device
OUR TEAM
William is a seasoned P&L operating executive and entrepreneur with over 35 years of leadership experience in medical device and biotechnology start-ups. He has a proven track record of commercially orchestrating and launching over a dozen transformative technologies globally and building high-performing, patient-focused teams. William has successfully raised more than $120 million in funding and has led key functions such as R&D, finance, manufacturing, business development, and commercial operations, with a focus on driving operational excellence in high-growth, scalable businesses.
Benjamin is a dynamic leader with a proven track record in corporate strategy, operational excellence, and transformational programs. With extensive experience across Fortune 500 companies, private equity, and startups, he has successfully driven impactful change and sustainable growth. As a former EY consultant, Benjamin has led multi-million-dollar transactions, implemented large-scale efficiency improvements, and consistently delivered measurable results. His expertise lies in designing and executing innovative strategies that enhance profitability, streamline operations, and build value.
Experienced advising in process improvement, business strategy, and program optimization. Experience spanning multiple industries within healthcare, including Payers, Providers, Biotechnology, Health Finance, Life Sciences, and Health Technology.
Don has extensive pharmaceutical experience in sales, marketing, business development, R&D and manufacturing in several pharmaceutical companies including BMS, Novartis, Daiichi, Shire, Elan and Zebec. His experience includes the divestiture and acquisition of several companies and numerous products. He has also been involved in the identification, evaluation and development of six startup companies including a women’s health company and has raised over $100 million.
Experienced early-stage healthtech investing, commercialization, and market access, insurtech; executive leadership and organizational management. Previously: EIR, Postdoc researcher in biomedical data science evaluating efficacy and value realization of predictive analytics.
Dr Smith is a Biotech/Pharmaceutical Executive, Board Director and Clinical/Scientific Advisor. Her breadth of experience covers 100+ clinical trials and 20+ regulatory approvals in multiple jurisdictions leading to product launches across diverse therapeutic areas including oncology, rare disease, cardiology, dermatology, neuroscience, and anti-infectives. In addition to growth and creation of R&D pipelines, Dr Smith’s successful record of business development includes acquisitions, divestitures, and partnership deals. Dr Smith has held various clinical and business roles over the past 20 years including President, CEO, Global Head R&D, and Chief Medical Officer. She has built companies from the ground up and is a strong advocate for women in science and diversity in the Boardroom.
Proven leader in fertility-focused healthcare sales and business development, with a track record of triple-digit revenue growth across multiple roles. Extensive experience in specialty pharmacy, molecular diagnostics, and fertility clinic solutions, consistently exceeding sales targets and launching strategic market expansions, including the successful West Coast launch of a major fertility division. Recognized for excellence in driving strategic partnerships and commercial agreements across multiple organizations.
Shireen has 25+ years of global leadership in commercial strategy and product lifecycle management, driving profitability and navigating complex markets across immunology, neurology, and vaccines. She has a proven track record of building and leading high-performing teams, and led or consulted on the launch of over 30 products
Michael is a seasoned life sciences executive with over 30 years of leadership experience across reproductive health, biotechnology, and medical devices. He has built and led global businesses in fertility and obstetrics, including serving as U.S. National Sales Director for Ferring’s Reproductive Health division—growing it to over $350 million—and as Global Head of Reproductive Health, overseeing a $1 billion franchise. Michael has launched market-leading therapies and served as CEO of Ferring Canada. He played a pivotal role in establishing FerGene, a gene therapy joint venture between Ferring and Blackstone, and later served as CEO of Evome, a publicly traded medical device company.
